Opportunistic Community Screening of Chronic Chagas Disease Using a Rapid Diagnosis Test in Pharmacies in Barcelona (Catalonia, Spain): Study Protocol and Pilot Phase Results

Aroa Silgado¹, Pau Bosch-Nicolau²,³, Adrián Sánchez-Montalvá²,³*, Ariadna Cervià⁴, Jordi Gomez-i-Prat², Guillermo Bagaria⁴, Cristina Rodriguez⁴, Lidia Goterris¹, Núria Serre-Delcor²,³, Inés Oliveira-Souto²,³, Fernando Salvador²,³, Israel Molina²,³ and Elena Sulleiro¹,³ on behalf of Chagas-farmacias study group

¹Department of Microbiology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain, ²Department of Infectious Diseases, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain, ³Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain, ⁴Official College of Pharmacists of Barcelona, Barcelona, Spain

Objectives: This study aimed to report the protocol and results from the pilot phase of an opportunistic CP-based CD screening program in Barcelona, Spain.

Methods: Three strategies according to recruitment approach were designed: passive, active and active-community. The study process consisted of signing the informed consent form, recording the patient’s data in a web-based database system, and performing the rapid test and blood collection on dry paper.

Results: Nineteen pharmacies participated and 64 patients were included during the pilot phase of the study. The rapid diagnostic test (RDT) was positive in 2/64 (3.13%) cases. Of the 49 DBS samples that arrived at the laboratory, 22 (45%) were collected incorrectly. After quantitative and qualitative assessment of the program, the dry paper sample and passive strategy were ruled out.

Conclusion: DBS sampling and the passive strategy are not suitable for CD screening in community pharmacies. There is a need to expand the number of participating pharmacies and individuals to determine whether conducting a RDT in community pharmacies is an effective screening method to increase access to CD diagnosis in a non-endemic area.

Keywords: Chagas disease, opportunistic screening, community pharmacies, rapid test, dried blood

INTRODUCTION

Chagas disease (CD), a life-threatening disease caused by the protozoan Trypanosoma cruzi, affects between 6 and 7 million people worldwide (1). It is estimated that nearly 10,000 deaths per year are directly caused by CD, with an estimated global cost of 8 billion dollars per year in lost productivity and health costs (2). Although endemic in Latin America, the number of CD cases reported in non-endemic countries has increased due to population movements (3). In Europe, Spain has the highest number of people infected by T. cruzi, with an estimated 52,000 cases; however, approximately 70% remain undiagnosed (4).
In the absence of the vector, CD can be transmitted via vertical transmission, blood transfusion and organ transplantation (5). Accordingly, health authorities in Spain have implemented different measures to control CD transmission: screening in blood banks is mandatory (Royal Decree 1088/2005) and some Spanish regions established CD screening protocols in pregnant women from Latin America, such as Valencia (in 2008) (6), Galicia (in 2008) (7) and Catalonia (in 2015) (8). However, no screening program to control CD in the general Latin American population is implemented in Spain and CD diagnosis relies on the general physician’s decision. Unfortunately, time constraints and the healthcare workers’ poor knowledge of CD, inefficiencies in the diagnosis and referral process flows, together with barriers to health system access and stigmatization, limit the current strategy to diagnose people with CD (9). To overcome these barriers, community-based activities for screening and case detection allow us to identify at-risk individuals and thus limit potential associated complications through early detection and appropriate treatment (10).

The vast majority of CD patients living in non-endemic areas are in the chronic stage of the disease (11). Diagnosis of this phase is by means of serological tests (12); for mass-screening surveys, a rapid, sensitive and easy to perform and interpret point of care diagnostic test would be valuable (13). Rapid diagnostic tests (RDTs) to detect antibodies against *T. cruzi* have been developed (14). Additionally, Dried Blood Spots (DBS) from finger-prick blood can be safely collected, stored at room temperature and sent under conventional courier conditions (15).

Community pharmacies (CPs) are a private healthcare resource that work in an integrated and coordinated manner in the management of health processes of the population. CPs are valuable assets for screening strategies due to territorial balance, consumer confidence, capillarity and social cohesion, professionalism and qualification, and their dense and interconnected network (16). Previous screening initiatives involving CPs have been carried out in Spain for other pathologies, such as opportunistic, under request, HIV screening programs and systematic colorectal cancer screening programs, with positive results (17, 18). To our knowledge, no CD screening program has been carried out in community pharmacies.

This study aimed to describe the protocol and results from the pilot phase of an opportunistic CD screening program at CPs in Barcelona (Catalonia, Spain).

**METHODS**

**Stakeholders, Target Population and Study Design**

This was an opportunistic CD screening intervention performed in CPs for people aged 18 or over, who are originally from one of the 21 endemic countries for CD, have been in an endemic area for more than 1 month or have a mother originally from an endemic country, even if the participant was born here. This project was financed by the Fundació Marató TV3 (project number 20182610) and supported by different referent organizations: College of Pharmacists of Barcelona, Vall d’Hebron University Hospital (HUVH), International Health Program of the Catalan Health Institute and XarChagas program. The pilot phase was performed from November 2019 to May 2021, at which time the strengths, weaknesses, opportunities, and threats (SWOT) analysis and relevant modifications to the final study protocol were made.

The screening study was carried out in three districts of Barcelona city (Figure 1) with a large population of Latin American migrants, according to the data of the last census in Barcelona (19): Nou Barris, Sants-Montjuïc and Horta-Guinardó. Participating pharmacies (N = 19) were selected based on different factors, including proactivity, experience in other screening programs (HIV and/or colorectal cancer), biological waste management training and certification, commitment to data protection procedures and facilities that ensure a comfortable and safe participant experience.

**Opportunistic Screening Strategies**

Three different strategies were used to approach the target population: 1) passive, 2) active and 3) active-community actions (Table 1). All participating CPs displayed posters offering CD screening at the entrance of the pharmacy, easily visible from the outside. In addition, informative leaflets were placed on the counter of the CP. Both posters and leaflets informed that the participant had the opportunity to take a free, rapid test to diagnose CD. In addition, the leaflets contained basic information about CD and reasons to be screened. Iconographic material was specially designed with the help of people affected with CD using a consensus decision-making process with the aim of drawing the attention of the Latin American population (Supplementary File S1).

i) Passive: implemented in Nou Barris, pharmacists had a wait-and-see attitude to recruit the target population, in this case the participant would request the RDT. ii) Active: implemented in Horta-Guinardó, pharmacists had a proactive attitude, where they explained and offered the RDT to Latin American consumers. iii) Active-community: implemented in those pharmacies located in the Sants-Montjuïc district. The iconographic material and the active attitude of the pharmacist were supplemented by the participation of community agents, who were tasked with conducting workshops/informative sessions in Latin American cultural associations and social meetings to encourage participation.

**Pharmacist Training**

Pharmacists received training in CD and RDT performance by completing a 3 h course imparted by physicians, microbiologists and community agents. This course explained general aspects of CD (including epidemiology, diagnosis and treatment); how to use and interpret the RDT; how to collect DBS samples; the use of the information system tools; as well as how to approach the participant. In this sense, an “Expert Patient” (Latin American community worker) trained the pharmacist in techniques to identify and approach Latin American consumers (Supplementary File S2).
Participating pharmacies were invited to complete a brief anonymous survey with general questions about CD before and after the training. This survey consisted of 18 questions divided into four specific areas (epidemiology, transmission, clinical presentation and diagnosis/treatment). Moreover, another brief anonymous satisfaction survey was performed to evaluate the training course.

Monitoring Plan
During the study, pharmacies received a personal visit from the training personnel (including a physician, a microbiologist, and a community health agent) to review the process, answer questions and correct any protocol deviations. To this end, a monitoring system was developed that included a guide for visiting and monitoring pharmacies (Standard Operational Procedure Monitoring Guideline). In addition to the on-site monitoring, pharmacies, lying in the last quartile according to the number of patients recruited, were telephoned and interviewed by an investigator regarding the hurdles hindering project implementation.

Dissemination and Communication
Different collaborating entities were contacted to inform them of the implementation of the screening program, such as the health centers in the selected neighborhoods, the department of health of the Government of Catalonia, and different community organizations.

During the project, online stakeholder meetings were scheduled every 3 months or sooner under request from any stakeholder. A mailing list and a group in an instant message app were created for rapid communication.

Information System Tools and Database
A web-based database platform was designed to record patient information, results obtained from the RDT and analysis of the DBS samples. This platform had personal authentication, search function, user privilege management and remote control.

The Official College of Pharmacists Information System centralized all information related to the processing and tracing of the RDT kits and DBS samples of the pharmacies and the microbiology laboratory of the HUVH.
Study Procedures
Screening Methods
The pharmacist’s role, regardless of the strategy, was to check exclusion/inclusion criteria, inform about the importance of screening for CD, and explain the project’s objective, procedure, possible results and referral interventions. If the participant agreed, he/she signed two copies of the informed consent form; one copy is kept in the investigator file in the CP and the other is given to the participant. Later, the participant answered a short survey about sociodemographic characteristics and CD risk factors, relatives with the disease and previous testing history. Then, the RDT is performed using a blood drop from a finger-prick. All the procedures were free of charge for the patient. In addition to the rapid test, DBS samples were obtained from finger-prick blood on filter-paper cards.

When the RDT result was negative, a specific information sheet was given to the participant. Additionally, he/she was informed, using plain language, of the test’s yield, including sensitivity and specificity, and was advised to consult their primary healthcare physician for the corresponding analyses. On the other hand, if the RDT was positive, pharmacists informed the patient about the need for a confirmatory test in a referral hospital. Upon acceptance, the pharmacist could, at that time, schedule an appointment at the HUVH Tropical Medicine Unit for the participant (Figure 2).

Laboratory Procedures (RDT and DBS Serology)
A previous analytical study was carried out to determine the sensitivity and specificity of the chosen rapid test, as well as for the analysis of the DBS samples via a serological technique (20).

The Trypanosoma Detect™ Rapid Test (InBios International, Inc., Seattle, WA) was selected for the rapid test in community pharmacies and performed according to manufacturer’s instructions. Briefly, one finger-prick blood drop is added to the test strip in the absorbent area, and then three or four drops of buffer solution are added to the same area. The results are read after 10 min.

Regarding DBS samples, between two or three additional drops of blood from the same finger-prick were used to fill one 8-mm-diameter circle on Whatman filter paper card (Whatman 903™ Specimen Collection Paper; GE Healthcare Ltd., Cardiff, United Kingdom). This procedure was repeated to fill a minimum of two circles. If the first finger-prick was not enough to fill the two required circles, the participant was asked about the possibility of making a second finger-prick.

Paper cards were dried at room temperature and then placed in a plastic bag with an anti-humidity sachet. All DBS samples were labeled with a code generated at the time of patient data entry to ensure sample traceability. In accordance with the pharmaceutical distribution system, DBS samples were delivered monthly to the microbiology laboratory of the HUVH for serological analysis.
DBSs were processed for analysis with the Elecsys Chagas assay (Roche Diagnostics, Manheim, Germany) for the determination of anti-\textit{T. cruzi} immunoglobulin G.

**Community Survey**

During March and July 2021, a survey of the target population was carried out to provide information regarding the acceptance of CD screening in CPs. This survey was conducted in the Sants-Montjuïc district, coinciding with the involvement of community agents in the project’s active strategy. Participants were asked whether they would want to be diagnosed for CD in pharmacies and to find out the reasons if not. Oral consent was requested before beginning the survey. No personal data was recorded for this study.

**Ethics**

This CD screening program follows the Public Health laws and the Organic Law on Data Protection. Review Board approvals were obtained from the Ethics Committee of the Vall d’Hebron Research Institute (PR(AG)230/2018), according to the principles expressed in the Declaration of Helsinki. Informed consent was obtained from all the participants prior to performance of the RDT. Patients were not involved in developing the research question, design or implementation of this analysis.

**Statistical Analysis**

Qualitative variables were expressed as absolute frequencies and percentages. Quantitative variables were described as mean or median and standard deviation or interquartile range according to normal distribution. Statistical analyses were done using SPSS Statistics v22.0 (SPSS Inc., Chicago, IL).

**RESULTS**

**Pharmacist’s Training**

Thirty-eight pharmacists attended the training course and completed the knowledge survey before and after receiving the training. All question categories showed an increase in the number of correct answers after having completed the course (Figure 3).

The satisfaction survey completed by the participating pharmacists included aspects related to organization, training activity, teaching staff and overall evaluation. The scoring scale ranged from 1 to 4 (4 being very positive). The specific aspects and overall median were between 3 and 4 (data not shown).

**Results From the Pilot Phase and SWOT Assessment**

In the pilot phase of the study, a total of 19 pharmacies were included: seven for the passive strategy, six for the active strategy and six for the active-community strategy. A total of 64 patients were included, of which 46 (71.9%) were women, and the median age was 40 years (Inter Quartile Range, 32.75-53). The main countries of origin of the participants were Bolivia (18/64; 28.1%), Ecuador (16/64; 25%) and Peru (12/64; 18.8%). Participants entered the program via communication from pharmacy staff (29/64; 45.3%), observation of the material in the pharmacy (27/64; 42.2%) and, to a lesser extent, through an acquaintance or family member (2/64; 3.1%) or information from community agents (1/64; 1.6%). In five cases (7.8%) this information was not registered. The RDT was positive in 2/64 (3.1%) cases. The characteristics of these two cases are resumed in Table 2.

Of the 64 patients included, a DBS sample was collected in 49 (76.56%) cases. Thirteen samples (13/49; 26.5%) were inadequately collected and could not be processed. Of the remaining 36 DBS samples processed for serological analysis, 26/36 (72.22%) were negative, 1/36 (2.78%) was positive and 9/36 (25%) were classified as invalid, which means that a reading error was obtained in the technique.

Due to the low number of patients recruited, a qualitative study of the acceptance of the project by potential participants was performed in a Latin American population recruited from public places, such as the Bolivian consulate. Of the 94 people surveyed, 27/94 (28.7%) answered that they considered a community pharmacy a suitable facility for CD diagnosis, while 28/94 (29.8%) preferred to be diagnosed in healthcare centers. However, the majority of participants (39/94; 41.5%) answered that they did not want to be tested for CD.

After completion of the pilot experience, a SWOT analysis was applied to improve aspects of the project (Figure 4).

---

**TABLE 2 | Characteristics of the two patients with a positive RDT result.**

| Patient code | Country of origin | Age | Gender | Serology by DBS | Conventional serology |
|--------------|-------------------|-----|--------|-----------------|----------------------|
| 1             | Bolivia           | 43  | Female | Reactive        | Positive             |
| 2             | Uruguay           | 54  | Male   | Non-Reacting    | Negative             |

---

**FIGURE 3** Percentage of correct answers by category before and after the training course. (Barcelona, Spain. 2019–2021). The questions were grouped into category: questions 1 and 2 on epidemiology, questions 3 to 7 on transmission, questions 8 to 12 on pathology, and questions 13 to 18 on diagnosis and treatment.
DISCUSSION

The under-diagnosis of people infected by *T. cruzi* responds to a complex matrix of interrelated factors, mainly attributed to the lack of knowledge of the infection and its transmission, fear and stigma, and a long asymptomatic phase (10). These factors complicate access to a diagnosis and, consequently, to treatment and clinical follow-up care (10). *In situ* screening interventions facilitate access to diagnostic tests and increase accessibility to potentially CD-affected people (21).

In the knowledge survey conducted on pharmacists before the course, the categories of “diagnosis and treatment” and “epidemiology” had the lowest percentage of correct answers. The work of (9), concluded that many physicians outside endemic areas have limited or no knowledge about CD and its implications. It is important to emphasize these aspects since, although the vector is not present in Spain, there are other routes of transmission that are particularly relevant for the transmission of CD in non-endemic areas, especially congenital transmission and *via* organ transplants and blood products (5).

A poor understanding of CD is one of the most important barriers to screening people susceptible to *T. cruzi* infection, especially a lack of accurate information about the disease, including the myth that CD is a synonym for death (22). Moreover, CD diagnosis produces a range of reactions in individuals, from skepticism to fear or anxiety (23). Therefore, a careful approach must be made when offering opportunistic screening to Latin American participants. To this end, our project included the collaboration of a CD “expert patient” with first-hand experience in the disease, who helped design the participant-centered approach and management plan, as well as the communication and dissemination plan (21, 24). Pharmacists were trained in the misconceptions and fears associated with CD. When dealing with the at-risk population, pharmacists are recommended to communicate using clear language, without stereotypes and with scientific rigor. Likewise, they must respect the views and knowledge of the participants. To this end, the figure of the “expert patient,” as well as iconographic materials, were essential for the implementation of this program. The involvement of community agents was intended to reduce the reluctance to participate and increase community engagement with the project. Therefore, their participation was aimed at eliminating the social stigma surrounding CD.

The SWOT analysis of the pilot phase highlighted several strengths of this program, such as coordination by experienced staff and training of pharmacists, as well as the free testing offered. However, several challenges were identified, including the reluctance to know their CD status and the lack of acceptance of positive RDT results.

The study was designed to compare three screening strategies with the hypothesis that pharmacist and community engagement would increase the number of patients screened. After the results from the pilot phase, and according to the participants and pharmacists’ opinions, the passive strategy was dropped.

The COVID-19 pandemic has, in many ways, disrupted the daily lives of people in affected countries, especially regarding social dynamics (25). Countries applied different measures to try to limit the spread of the virus; in Spain, different states of alarm were decreed over time with perimeter closures, quarantines, curfews… as well as the adoption of sanitary measures, such as safety distance, reduced personal contact… Moreover, pharmacies have seen an increase in the services offered as a result of the pandemic, such as antigen and serological tests. This fact may explain, in part, the low recruitment speed observed in this pilot phase of the project.

Rapid diagnostic tests reduce the turnaround time, and with a proper referral procedure, reduce losses to follow-up (26). RDTs
are easily implemented at the community level, but the sensitivity reported is not high enough to be used as the sole screening technique. Based on this fact, in the present study, a strategy was selected based on the combination of the RDT with a serology test using DBS, which can reach a sensitivity up to 97% (20).

In 15/64 (23.44%) of the cases it was not possible to collect the DBS sample for serology analysis. This may be due to the fact that, although finger pricking seems to be a simple act, the fact of having to repeat it in order to obtain the DBS sample may be a reason for participants to refuse. In addition, although in 49 cases it was possible to collect DBS samples, 13 of them were collected improperly (either both circles were not full or only one circle was impregnated). Unfortunately, after the pilot phase, the project steering committee decided to remove this procedure as it was considered to hinder the logistics of the screening process.

Similarly, in non-endemic countries, the choice of using RDTs for screening should be followed by confirmation of the results in a reference laboratory (27). Challenges related to the follow-up of patients by specialized units, especially in those with a positive RDT, can be a real problem that can hinder the effectiveness and success of the screening program. In order to try to lose as few patients as possible between screening and subsequent clinical follow-up, the pharmacy booked an appointment for diagnosis in the referral center. Participants not attending the scheduled visit were contacted by phone or e-mail to offer them a new visit.

During the pilot phase, two participants had a positive result on the RDT. Both attended the subsequent visit at the referral unit at HUVH, indicating that acquiring the appointment at the pharmacy is a successful method to avoid the risk of losing the patient. The positive RDT result of patient 6 was not confirmed neither by serology from DBS and serum samples. On the other hand, participants with negative results were carefully explained the meaning of the result and encouraged to perform the diagnosis at his/her primary care center.

Implementation of screening actions for CD, coupled with early management of the disease, is a cost-effective strategy (28); however, cost assessment prior to the large-scale implementation of any strategy is essential for planning and refining procedures and investment efforts (29).

To conclude, DBS sampling and the passive strategy are not suitable for CD screening in community pharmacies. There is a need to expand the number of participating pharmacies and individuals to determine whether conducting a RDT in community pharmacies is an effective screening method to increase access to CD diagnosis in a non-endemic area.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics Committee of the Vall d’Hebron Research Institute. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

Conceptualization: AS-M and IO-S. Data curation and investigation: AS, PB-N, AS-M, AC, JG, GB, CR, LG, NS-D, IO-S, FS, IM, and ES. Methodology: AS, AS-M, IO-S, AC, JG, GB, and CR. Writing—original draft: AS and PB-N. Writing—review and editing: AS, PB-N, AS-M, AC, JG, GB, CR, LG, NS-D, IO-S, FS, IM, and ES. Supervision: AS-M. Funding acquisition: IO-S. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work has been supported by the Fundació la Marató TV3 (project number 481/U/2018).

**CONFLICT OF INTEREST**

The authors declare that they do not have any conflicts of interest.

**ACKNOWLEDGMENTS**

The authors thank Helena Kruyer for her assistance with the English.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.ssph-journal.org/articles/10.3389/ijph.2022.1605386/full#supplementary-material

**Supplementary Figure S1** | Iconographic material used in this program (in Spanish). (A) Poster displayed at the entrance of the pharmacy, visible from the outside. (B) Leaflets with brief information about Chagas disease. (Barcelona, Spain. 2019–2021).

**Supplementary Figure S2** | Guidelines for approaching people from countries endemic for Chagas disease. (Barcelona, Spain. 2019–2021).
REFERENCES

1. World Health Organization. Chagas Disease (American Trypanosomiasis) [Internet] (2020). Available from: http://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis) (Accessed May 17, 2022).

2. Lee BY, Bacon KM, Bottazzi ME, Hotze PJ. Global Economic burden of Chagas Disease: A Computational Simulation Model. *Lancet Infect Dis* (2013) 13(4):342–8. doi:10.1016/S1473-3099(13)70002-1

3. Stanaway JD, Roth G. The Burden of Chagas Disease: Estimates and Challenges. *Glob Heart* (2015) 10(3):139–44. doi:10.1016/j.ghart.2015.06.001

4. Navarro M, Reguero L, Subirá C, Blázquez-Pérez A, Requena-Méndez A. Estimating Chagas Disease Prevalence and Number of Underdiagnosed, and Underdetected Individuals in Spain. *Trav Med Infect Dis* (2022) 47:102284. doi:10.1016/j.tramid.2022.102284

5. Pérez-Molina J, Molina I. Chagas Disease. *Lancet* (2018) 391:82–94. doi:10.1016/S0140-6736(17)31612-4

6. Conselleria de Salut CV. Enfermedad de Chagas importada. Protocolo de actuación en la Comunitat Valenciana. Valencia: Enfermedades Emergentes (2009).

7. Galicia X. Protocolo de cribado da enfermidade de chagas en mulleres embarazadas. Santiago de Compostela: Xunta de Galicia (2014).

8. Ciruela Navas P, Jaque Checa M. Protocolo de cribado diagnostico y tratamiento de la enfermedad de chagas. *Santos J, J*, et al. Screening for Major Diseases in a Non-Endemic Country. *Plos Negl Trop Dis* (2019) 13(12):e0007937–16. doi:10.1371/journal.pntd.0007937

9. Gómez i Prat J, Peremiquel-Trillas P, Claveria Guix I, Choque E, Oliveira-Souto I, Serre-Delcor N, et al. A Community-Based Intervention for the Detection of Chagas Disease in Barcelona, Spain. *J Community Health* (2019) 44(4):704–11. doi:10.1007/s10900-019-00684-z

10. Pérez-Molina JA, Norman F, López-Vélez R. Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment. *Carr Infect Dis Rep* (2012) 14(3):263–74. doi:10.1159/000341809

11. World Health Organization. Guidelines for the Diagnosis and Treatment of Chagas Disease. Washington, DC: PAHO (2019).

12. Shah V, Ferrufino L, Gilman RH, Ramirez M, Saenza E, Malaga E, et al. Field Evaluation of the InBios Chagas Detection Plus Rapid Test in Serum and Whole Blood Specimens in Bolivia. *Clin Vaccine Immunol* (2014) 21(12):1645–9. doi:10.1128/CVI.00609-14

13. Anghelbaen A, Buonfrate D, Cruciani M, Jackson Y, Alonso-Padilla J, Gascon J, et al. Rapid Immunochromatographic Tests for the Diagnosis of Chronic Chagas Disease in At-Risk Populations: A Systematic Review and Meta-Analysis. *Plos Negl Trop Dis* (2019) 13(5):e0007271–15. doi:10.1371/journal.pntd.0007271

14. McClendon-Weary B, Putnick DL, Robinson S, Yeung E. Little to Give, Much to Gain—What Can You Do with a Dried Blood Spot? *Carr Environ Health Rep* (2020) 7(3):211–21. doi:10.1007/s40572-020-00289-y

15. Ayorinde AA, Porteous T, Sharma P. Screening for Major Diseases in Community Pharmacies: A Systematic Review. *Int J Pharm Prac* (2013) 21(6):349–61. doi:10.1111/ijpp.12041

16. Fernandez-Lopez L, Reyes-Urrea J, Conway A, Saz J, Morales A, Quezadas J, et al. The Contribution of HIV point-of-care Tests in Early HIV Diagnosis: Community-Based HIV Testing Monitoring in Catalonia, 1995 to 2018. *Eurosurveillance* (2020) 25(43):1–11. doi:10.2807/1560-7917.ES.2020.25.43.1900424

17. Ibáñez-Sanz G, Mílà N, Vidal C, Rocamora J, Moreno V, Sanz-Pamplona R, et al. Positive Impact of a Fecal-Based Screening Programme on Colorectal Cancer Mortality Risk. *Plos One* (2021) 16(6):e0253369–14. doi:10.1371/journal.pone.0253369

18. Instituto d’Estadística de C. Población Extranjera [Internet] (2020). Available from: https://www.idescat.cat/poblacioestranjera/?fb=10&geoo=mun%3A080193&nac=d314#Plegable=geo (Accessed May 17, 2022).

19. Silva-Silgado A, Gual-Gonzalez L, Sánchez-Montalvá A, Oliveira-Souto I, Goterris L, Serre-Delcor N, et al. Analytical Evaluation of Dried Blood Spot and Rapid Diagnostic Test as a New Strategy for Serological Community Screening for Chronic Chagas Disease. *Front Cell Infect Microbiol* (2021) 11:736630. doi:10.3389/fcimb.2021.736630

20. Gómez i Prat J, Peremiquel-Trillas P, Guiu IC, Mendivelso JC, Choque E, de los Santos JJ, et al. Comparative Evaluation of Community Interventions for the Immigrant Population of Latin American Origin at Risk for Chagas Disease in the City of Barcelona. *Plos One* (2020) 15(7):e0235466–15. doi:10.1371/journal.pone.0235466

21. Avaria A, Gómez i Prat J. Si Tengo Chagas es Mejor que me Muera El Desafío de Incorporar una Aproximación Sociocultural a la Atención de Personas Afectadas por la Enfermedad de Chagas. *Enferm Emerg* (2008) 10(1):40–5.

22. Echeverria LE. Marcus R, Novick G, Sosa-Estani S, Ralston K, Zaidel EL, et al. WHF IASC Roadmap on Chagas Disease. *Glob Heart* (2020) 15(1):26–31. doi:10.5334/gbh.484

23. Velarde-Rodriguez M, Avaria-savedra A, Gomez-i-Prat J, Jackson Y, De Oliveira Junior AW, Camps-carmona B, et al. Need of Comprehensive Health Care for T. Cruz Infected Immigrants in Europe. *Rev Soc Bras Med Trop* (2009) 42(2):92–5.

24. Fontana Sierra L. Pandemic and Rearculturalization of Social Relations. *Periferia* (2020) 25(2):101. doi:10.5565/rev/periferia.770

25. Gubbins PO, Klepser ME, Dering-Anderson AM, Bauer KA, Darin KM, Klepser S, et al. Point-of-care Testing for Infectious Diseases: Opportunities, Barriers, and Considerations in Community Pharmacy. *J Am Pharm Assoc* (2014) 54(2):163–71. doi:10.1331/JPhA.2014.13167

26. Sánchez-Camargo CL, Albajar-Viñas P, Wilkins PP, Nieto J, Leiba DA, Paris L, et al. Comparative Evaluation of 11 Commercialized Rapid Diagnostic Tests for Detecting Trypanosoma Cruzi Antibodies in Serum banks in Areas of Endemicity and Nonendemicity. *J Clin Microbiol* (2014) 52(7):2506–12. doi:10.1128/JCM.00144-14

27. Roquena-Méndez A, Asserson E, Jackson Y, Angheben A, Moore D, et al. Cost-effectiveness of Chagas Disease Screening in Latin American Migrants at Primary Health-Care Centres in Europe: a Markov Model Analysis. *Lancet Glob Health* (2017) 5(4):e439–47. doi:10.1016/S2214-109X(17)30073-6

28. Hoomans T, Severens JL. Economic Evaluation of Implementation Strategies in Health Care. *Implement Sci* (2014) 9:168. doi:10.1186/s13012-014-0168-y

Copyright © 2022 Silgado, Bosch-Nicolau, Sánchez-Montalvá, Cervià, Gómez-i-Prat, Bagaria, Rodriguez, Goterris, Serre-Delcor, Oliveira-Souto, Salvador, Molina and Sullleiro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.